Which inhaled corticosteroid and long-acting β-agonist combination is better in patients with moderate-to-severe asthma, a dry powder inhaler or a pressurized metered-dose inhaler?

Masato Murakia Department of Respiratory Medicine and Allergology, Kindai University Nara Hospital, Ikoma, Japan; Correspondence[email protected]

Kyuya Gosea Department of Respiratory Medicine and Allergology, Kindai University Nara Hospital, Ikoma, Japan;

Soichiro Hanadaa Department of Respiratory Medicine and Allergology, Kindai University Nara Hospital, Ikoma, Japan;

Hirochiyo Sawaguchia Department of Respiratory Medicine and Allergology, Kindai University Nara Hospital, Ikoma, Japan;

Yuji Tohdab Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine, Osakasayama, Japan

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Yu Nakanishi, Hiroshi Iwamoto, Shintaro Miyamoto, Satoshi Nakao, Naoko Higaki, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Yasushi Horimasu, Takeshi Masuda, Naoko Matsumoto, Taku Nakashima, Yojiro Onari, Kazunori Fujitaka, Yoshinori Haruta, Hironobu Hamada, Soichiro Hozawa & Noboru Hattori. (2022) Association Between Patient Preference for Inhaler Medications and Asthma Outcomes. Journal of Asthma and Allergy 15, pages 1539-1547.
Read now

John N Pritchard. (2020) The Climate is Changing for Metered-Dose Inhalers and Action is Needed. Drug Design, Development and Therapy 14, pages 3043-3055.
Read now

Articles from other publishers (6)

Mona Al-Ahmad & David Webb. (2022) A prospective study of switching asthma patients from a Fixed-Dose Combination (FDC) Inhaled Corticosteroid [ICS]/Long-Acting Beta Agonist [LABA] therapy delivered by Dry Powder Inhaler (DPI) to ICS/LABA delivered by pressurised Metered Dose Inhaler (pMDI). Respiratory Medicine 194, pages 106771.
Crossref

Daniele Pernigotti, Carol Stonham, Sara Panigone, Federica Sandri, Rossella Ferri, Yasemin Unal & Nicolas Roche. (2021) Reducing carbon footprint of inhalers: analysis of climate and clinical implications of different scenarios in five European countries. BMJ Open Respiratory Research 8:1, pages e001071.
Crossref

Duncan Keeley, Jane E. Scullion & Omar S. Usmani. (2020) Minimising the environmental impact of inhaled therapies: problems with policy on low carbon inhalers. European Respiratory Journal 55:5, pages 2001122.
Crossref

Aaron B. Holley & Linda Rogers. 2020. Difficult To Treat Asthma. Difficult To Treat Asthma 91 106 .

Omar S Usmani, Jane Scullion & Duncan Keeley. (2019) Our planet or our patients—is the sky the limit for inhaler choice?. The Lancet Respiratory Medicine 7:1, pages 11-13.
Crossref

Which inhaled corticosteroid and long-acting β-agonist combination is better in patients with moderate-to-severe asthma, a dry powder inhaler or a pressurized metered-dose inhaler?

Articles from other publishers (6)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Which inhaled corticosteroid and long-acting β-agonist combination is better in patients with moderate-to-severe asthma, a dry powder inhaler or a pressurized metered-dose inhaler?

Citations (8)

Read on this site (2)

Articles from other publishers (6)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date